Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAGE-039
- Development stage
- Preclinical
- Lead developer
- Sage Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAGE-039 is an investigational oral small molecule developed by Sage Therapeutics as part of its NMDA receptor negative allosteric modulator (NAM) platform. It is designed to selectively inhibit subtypes of the N-methyl-D-aspartate receptor (NMDAR), a key component in glutamate signaling pathways implicated in various neurodevelopmental and neuropsychiatric disorders. The compound represents one of several approaches Sage is pursuing to target disorders linked to dysregulated glutamatergic neurotransmission, such as schizophrenia, depression, and other neurodevelopmental conditions. As of mid-2025, SAGE-039 remains in preclinical development with ongoing evaluation for potential use in treating neurodevelopmental disorders[1][2][3][4][8].
- Other names
- SAGE-039SAGE039SAGE 039
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on SAGE-039.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAGE-039.